Format

Send to

Choose Destination
ILAR J. 2017 Dec 1;58(2):172-189. doi: 10.1093/ilar/ilx028.

The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis.

Author information

1
Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas.
2
Center for Vaccines and Immunity, The Research Institute, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
3
College of Medicine, The Ohio State University, Columbus, Ohio.
4
Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina.
5
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
6
Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina.

Abstract

Chimpanzees (Pan troglodytes) have contributed to diverse fields of biomedical research due to their close genetic relationship to humans and in many instances due to the lack of any other animal model. This review focuses on the contributions of the chimpanzee model to research on hepatitis viruses where chimpanzees represented the only animal model (hepatitis B and C) or the most appropriate animal model (hepatitis A). Research with chimpanzees led to the development of vaccines for HAV and HBV that are used worldwide to protect hundreds of millions from these diseases and, where fully implemented, have provided immunity for entire generations. More recently, chimpanzee research was instrumental in the development of curative therapies for hepatitis C virus infections. Over a span of 40 years, this research would identify the causative agent of NonA,NonB hepatitis, validate the molecular tools for drug discovery, and provide safety and efficacy data on the therapies that now provide a rapid and complete cure of HCV chronic infections. Several cocktails of antivirals are FDA approved that eliminate the virus following 12 weeks of once-per-day oral therapy. This represents the first cure of a chronic viral disease and, once broadly implemented, will dramatically reduce the occurrence of cirrhosis and liver cancer. The recent contributions of chimpanzees to our current understanding of T cell immunity for HCV, development of novel therapeutics for HBV, and the biology of HAV are reviewed. Finally, a perspective is provided on the events leading to the cessation of the use of chimpanzees in research and the future of the chimpanzees previously used to bring about these amazing breakthroughs in human healthcare.

KEYWORDS:

HAV; HBV; HCV; antiviral; chimpanzee; hepatitis; nonhuman primate; vaccine

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center